Immunic, Inc.

NASDAQ:IMUX

1.18 (USD) • At close November 7, 2024
Bedrijfsnaam Immunic, Inc.
Symbool IMUX
Munteenheid USD
Prijs 1.18
Beurswaarde 106,293,220
Dividendpercentage 0%
52-weken bereik 0.945 - 2.11
Industrie Biotechnology
Sector Healthcare
CEO Dr. Daniel Vitt Ph.D.
Website https://www.immunic-therapeutics.com

An error occurred while fetching data.

Over Immunic, Inc.

Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune

Vergelijkbare Aandelen

DermTech, Inc. logo

DermTech, Inc.

DMTK

0.094 USD

Pliant Therapeutics, Inc. logo

Pliant Therapeutics, Inc.

PLRX

15.19 USD

Kronos Bio, Inc. logo

Kronos Bio, Inc.

KRON

0.9 USD

Marinus Pharmaceuticals, Inc. logo

Marinus Pharmaceuticals, Inc.

MRNS

0.359 USD

MoonLake Immunotherapeutics logo

MoonLake Immunotherapeutics

MLTX

50.67 USD

Personalis, Inc. logo

Personalis, Inc.

PSNL

4.32 USD

Sanara MedTech Inc. logo

Sanara MedTech Inc.

SMTI

33.91 USD

Lyra Therapeutics, Inc. logo

Lyra Therapeutics, Inc.

LYRA

0.265 USD

Hyperfine, Inc. logo

Hyperfine, Inc.

HYPR

0.97 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)